Back to today’s briefing

Story perspectives

GLP-1 Medications: Alarming Muscle Loss and Misuse Risks

7/22/2025

23 2

Summary

Story summary

GLP-1 medications, such as semaglutide and tirzepatide, may cause alarming muscle loss—accounting for 25-40% of total weight loss—while failing to enhance cardiorespiratory fitness. In South Korea, the alarming rise in misuse for cosmetic reasons raises concerns, as prescriptions are frequently given without thorough assessments, jeopardizing public health and access for those in genuine need.

1 of 1

Story summary

GLP-1 medications, such as semaglutide and tirzepatide, may cause alarming muscle loss—accounting for 25-40% of total weight loss—while failing to enhance cardiorespiratory fitness. In South Korea, the alarming rise in misuse for cosmetic reasons raises concerns, as prescriptions are frequently given without thorough assessments, jeopardizing public health and access for those in genuine need.